AUSTIN, Texas — August 14, 2025 — Leads & Copy — Cassava Sciences, Inc. (NASDAQ: SAVA) reported its financial results for the second quarter ended June 30, 2025, along with a business update highlighting the advancement of simufilam for TSC-related epilepsy.
The company’s net loss was $44.2 million, compared to a net income of $6.2 million for the same period in 2024. Cash and cash equivalents totaled $112.4 million as of June 30, 2025. A clinical study for simufilam is expected to begin in H1 2026.
Cassava Sciences is focused on developing treatments for central nervous system disorders. The company’s lead drug candidate, simufilam, is being developed for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.
Rick Barry, President and CEO of Cassava, noted the transformational year for the company and the initiation of a new program focused on TSC-related epilepsy.
Dr. Joseph Hulihan has been appointed as Chief Medical Officer, and Angélique Bordey, PhD, joined as Senior Vice President, Neuroscience. Jack Moore, PhD, also joined the Company as SVP, Clinical Development.
Net cash used in operations was $16.3 million during the first half of 2025 and is expected to be $47 to $51 million in the second half, which includes a $31.25 million estimated loss contingency related to potential settlement of securities litigation.
Sandya von der Weid, Investor Contact, svonderweid@lifesciadvisors.com. Eric Schoen, Chief Financial Officer, (512) 501-2450, ESchoen@CassavaSciences.com.
Source: Cassava Sciences, Inc.
